

**REMARKS**

**Election/Restrictions**

The Examiner has alleged that restriction is required under 35 U.S.C. 121 and 372, asserting that the present application contains the following inventions or groups of inventions arguably not so linked as to form a single general inventive concept under PCT Rule 13.1.:

Group I. Claims 1 -10 drawn to products. Further election of a single compound is required.

Group II. Claims 16 drawn to methods. Further election of a single compound is required.

While the Applicants disagree with the Examiner that restriction is required, Applicants elect Group I. Moreover, applicants respectfully request withdrawal of the restriction in view of the present amendment cancelling Claim 16.

In further response to the Office Action dated March 2, 2009, Applicants elect species 2-[1-Phenyl-2-(2-trifluoromethyl-phenyl)-ethyl]-morpholine (Example 12).

Entry of the above-specified amendments to the specification and claims is requested. Applicants submit that Claims 8-10 are in condition for allowance, which is respectfully requested.

If the Examiner has any questions, the Examiner is invited to contact the undersigned at (317)  
651-1266.

Respectfully submitted,

/Tonya L. Combs/  
Tonya L. Combs  
Attorney for Applicants  
Registration No. 57,909  
Phone: 317-651-1266

Eli Lilly and Company  
Patent Division/TLC  
P.O. Box 6288  
Indianapolis, Indiana 46206-6288

April 2, 2009\_\_\_\_\_